MLAB · Mesa Laboratories, Inc.

Period Performance

Period Performance

For the three months ended December 31, 2025, Mesa Laboratories reported total revenues of $65.1 million, a 3.6% increase compared to $62.8 million in the prior-year period. Gross profit rose 5.1% to $41.8 million, with gross margin improving to 64.2% from 63.3%, driven by favorable mix and cost savings in Clinical Genomics and higher volumes in Biopharmaceutical Development. Operating income surged 38.0% to $8.0 million, as operating expenses declined slightly (0.5%) due to lower professional services and consulting fees. Net income swung to $3.6 million from a loss of $(1.7 million) in the prior year, reflecting improved operating performance and lower non-operating expenses.

For the nine-month period, revenues grew 3.7% to $185.4 million. Gross profit increased 3.2% to $116.1 million, but gross margin slipped to 62.6% from 62.9%, with a 0.8 percentage point headwind from foreign currency translation and tariffs. Operating expenses rose 2.8%, driven by higher bad debt allowances in China and increased personnel costs, partially offset by lower integration costs. Net income more than doubled to $10.8 million from $5.1 million, aided by a $5.8 million unrealized foreign currency gain on an intercompany loan.

Segment Dynamics

• Sterilization and Disinfection Control: Revenues grew 6.0% (Q3) and 5.5% (YTD), supported by FX tailwinds, higher sales volumes, and price increases. Excluding FX, organic growth was approximately 2.4% (Q3) and 2.3% (YTD). Gross margin was flat to slightly down, with the prior year benefiting from GKE inventory step-up amortization.
• Biopharmaceutical Development: Revenues jumped 17.5% (Q3) and 10.2% (YTD), driven by strong hardware sales (peptides, immunoassays) and FX. Gross margin improved 0.5 points in Q3 but declined 4.1 points YTD due to FX, tariffs, and unfavorable product mix (higher hardware share).
• Calibration Solutions: Revenues fell 2.5% in Q3 due to a tough prior-year comp in renal care, but grew 3.9% YTD on contract renewals and price increases. Gross margin declined 1.0 point (Q3) and 1.1 points (YTD) on unfavorable mix and higher personnel costs.
• Clinical Genomics: Revenues declined 7.1% (Q3) and 6.7% (YTD) due to ongoing China weakness. Excluding China, revenues grew 2.4% (Q3) and 8.4% (YTD). Gross margin improved sharply—5.6 points (Q3) and 1.7 points (YTD)—from cost savings, manufacturing efficiencies, and favorable geographic mix.

Forward View

Management expects challenges in China to persist through the end of fiscal year 2026 and likely into fiscal year 2027. The company continues to focus on organic growth, cost reduction initiatives, and strategic acquisitions. Interest expense is expected to remain elevated due to the higher rate on the Credit Facility compared to the retired Notes, with approximately $10.2 million in cash interest expected over the next twelve months. The company amended its Credit Facility in October 2025 to reduce the interest rate spread, which is expected to save about $0.4 million annually. No material changes to market risk exposure were noted.

Cash Flow Quality

Cash Flow Quality

Operating cash flow (CFO) of $28.9M comfortably exceeded net income of $10.8M, indicating strong cash generation from operations. The CFO-to-NI ratio of 2.7x is healthy, driven largely by non-cash charges (depreciation & amortization of $17.5M, stock-based compensation of $11.1M).

Capex of $2.8M represents only 9.7% of CFO, reflecting a low capital intensity business model. Free cash flow (CFO minus capex) is approximately $26.1M, but not explicitly stated. Working capital changes consumed $8.9M of cash, primarily due to inventory buildup ($3.5M) and a decline in accrued liabilities ($3.5M).

Capital returns: dividends of $2.6M are well-covered by FCF. No share repurchases occurred. The company used $97.5M to repurchase and settle convertible notes, funded largely by new debt borrowings of $107.5M.

Overall, cash flow quality is solid with operational cash flow providing ample coverage for capex and dividends, though working capital headwinds warrant monitoring.